TABLE 1.

Characteristics of the initial and second infection in five kidney transplant recipients

	Age	Gender	Time between transplant and the first infection	Immunosuppression at the first infection	Severity of the first infection a	Days of vaccine completion after the first infection	Interval between infections	Immunosuppression at the second infection	Severity of the second infection a
1	66	Male	233 days after	MMF 750 mg two times daily Tacrolimus (18.3)b	3	NA	210 days	MMF 500 two times daily Tacrolimus (9.1) Prednisone 10 mg daily	3
2 c	45	Male	78 days after	MPA 720 mg two times daily Prednisone 10 mg daily Tacrolimus (9.3)	3	240 days	287 days	MPA 720 mg two times daily Prednisone 10 mg daily Tacrolimus (2.3)	2
3 c	43	Female	172 days before	None	2	233 days (61 days after transplant)	349 days (177 days after transplant)	MPA 720 mg two times daily Tacrolimus (7.7)	2
4 c	53	Male	464 days after	MMF 250 mg two times daily Tacrolimus (7.8) prednisone 5 mg daily	3	NA	365 days	MMF 1000 mg two times daily Tacrolimus (7.1)	3
5 c	30	Male	149 days before	None	2	NA	308 days (159 days after transplant)	MPA 540 mg two times daily Tacrolimus (7.2) Prednisone 2.5 mg daily	2

Abbreviations: MMF, mycophenolate mofetil; MPA, mycophenolic acid; NA, Not applicable.

^a WHO scale: 1, no impairment; 2, impairment but not hospitalized; 3, hospitalized, no oxygen support; 4, hospitalized, required supplemental oxygen; 5, hospitalized and required high‐flow nasal cannula or noninvasive positive pressure ventilation; 6, required mechanical ventilation; 7, additional support.

^b Tacrolimus level.

^c Induction immunosuppression for all patients here included high‐dose corticosteroids, basiliximab, and anti‐thymocyte globulin.